The treatment outcome of brentuximab vedotin (BV) has not been related with CD30 expression in previous studies enrolling patients with a wide range of CD30 expression level.
Introduction
Brentuximab vedotin (BV) is an anti-CD30 monoclonal antibody conjugated with the microtubule-disrupting agent monomethyl auristatin E [1] . CD30, a transmembrane glycoprotein, is uniformly expressed in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). BV has been previously approved for the treatment of relapsed or refractory HL and systemic ALCL based on its high objective response rates of 75% and 86% in relapsed or refractory HL and systemic ALCL, respectively [2, 3] . Subsequent to that approval, the efficacy of BV was evaluated in various subtypes of non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), peripheral T-cell lymphoma (PTCL), mycosis fungoides (MF), and various cutaneous T-cell lymphomas [4] [5] [6] [7] [8] . All of these studies enrolled patients with a wide range of CD30 expression levels, and their response rates were unrelated to CD30 expression level of tumor cells. For example, 70% of patients with cutaneous T-cell lymphomas, including MF, responded to BV, and the different cutoff values (< 10%, 10%-50%, and  50%) were unrelated to response rate in MF, although patients with < 5% CD30 expression had a lower response likelihood compared with patients with  5% expression [4, 5] . The response rate to BV was also unrelated with the level of CD30 expression in DLBCL (44%) and PTCL (41%), and these response rates were higher in PMBCL patients (13.3%) even though PMBCL is typically characterized by high CD30 expression [6] [7] [8] . Accordingly, these previous studies enrolling patients with a wide range of CD30 expression levels may not provide sufficiently robust information on the association between CD30 expression and response to BV. Thus, we designed a phase II study to evaluate the efficacy of BV as a salvage therapy in relapsed or refractory patients with high-CD30-expressing NHL other than ALCL. Although a precise definition of high CD30 expression has not been established, we defined cases having ≥ 30% Korean Cancer Association This article is protected by copyright. All rights reserved. various subtypes of NHL [9] [10] [11] [12] .
CD30, a member of the tumor necrosis factor receptor superfamily, is known to exert a variety of biological functions, including cell cycle regulation, apoptosis, and activation of nuclear factor -light-chain-enhancer of activated B cells (NF-B). CD30 is preferentially expressed in activated B cells; however, T-and NK-cells are also reported to express CD30 [13] . In addition, Epstein-Barr virus (EBV) infection-associated lymphomas could express CD30 because latent membrane protein 1, a critical element of EBV infection, may promote CD30 expression [14] . Accordingly, previous studies have shown approximately 40% of CD30 expression in extranodal natural killer/T-cell lymphoma (ENKTL), in which LMP1 is commonly expressed [15, 16] . CD30 expression is also associated with activation of interferon regulatory factor 4, also known as multiple myeloma oncogene 1 (MUM1), because CD30 activation may promote activities of the NF-B leading to MUM1 expression [17] . This positive feedback signaling from CD30 to MUM1 might contribute to tumor aggressiveness, because MUM1 binds directly to the MYC promoter region leading to cell proliferation [18, 19] . Thus, EBV positivity and MUM1 expression of lymphoma cells may influence response to BV due to their close relationship with CD30 expression.
We analyzed response rates in accordance with CD30 positivity and presented the results of this study after the completion of enrollment at the annual meeting of American Society of Hematology in 2017 [20] . For this final report, we re-evaluated the pathology subtypes and performed the post-hoc analysis evaluating the associations of EBV positivity and MUM1 expression with response to BV and survival outcome to find biomarkers. We also re-evaluated Korean Cancer Association This article is protected by copyright. All rights reserved.
the treatment response to determine the interpatient heterogeneity of response as a post-hoc analysis, and updated the survival status on November 30, 2018. 
Materials and Methods

Study design
Eligibility
There were five eligibility criteria. each of the study sites after they reviewed various cutoff values for 'positive' and 'strong positive' of CD30 expression across various subtypes of NHL [4] [5] [6] [7] [8] [9] [10] [11] [12] .
Statistical analysis
Sample size was calculated to reject the null with a 20% overall disease control rate but increased to favor of a target rate of 40% with significance 0.05 and power 80% using Simon's
Minimax two-stage design [22] . Thus, if the rate was less than 4/18 during the first stage, the study would be stopped. If not, patient recruitment would be continued until n=33. Patients' clinical characteristics, demographics, and treatment outcomes were analyzed based on the NHL subtype, and chi-squared tests were used to evaluate their relationships with outcomes.
OS was calculated from the first date of BV infusion to final follow-up or death from any cause.
PFS was calculated from the first date of BV infusion to the date of disease progression or death from any cause. Median potential follow-up time with 95% confidence interval (CI) was determined using the Kaplan-Meier method [23] . Survival was estimated based on KaplanMeier curves and compared using the log-rank test. Two-sided p < 0.05 was considered statistically significant.
Biomarker analysis
Quantified CD30 expression from tumor cells was compared with determined response to BV. Immunohistochemistry was performed on 4-m paraffin sections following routine protocols using a fully automated platform at each institute; CD30 was detected using a readyto-use antibody (clone BerH2, Dako, Carpinteria, CA). EBV in situ hybridization and MUM1 expression were analyzed in patients who had tissue sample available for analysis. The presence of EBV-positive tumor cells was considered EBV positivity regardless of its percentage Korean Cancer Association This article is protected by copyright. All rights reserved.
whereas MUM1-positivity was defined as more than 30% of tumor cells were positively stained.
Immunohistochemistry for MUM1 (MUM1p, Dako) was also performed for exploratory biomarker development. Differences in biomarkers between responder subgroups were compared via post-hoc analysis using the chi-squared test.
Ethical statement
The study was conducted by the Consortium for Improving Survival of Lymphoma 
Results
Patients
In total, 33 patients were enrolled between March 2015 and January 2017 from five hospitals belonged to the CISL. Their median age at enrollment was 56 years (range, 27 to 73 years); other characteristics at enrollment are summarized in Table 1 . Stage III/IV patients accounted for 79% (26/33) of the sample and 70% had elevated levels of serum lactate dehydrogenase. All patients were treated with at least one line of salvage chemotherapy. The median number of prior therapies was three (range, 2 to 10) and seven patients relapsed after autologous SCT. At enrollment, 10 patients had relapsed after their last chemotherapy and 22
were refractory after previous treatment ( Table 1 ). The most common subtypes were DLBCL Korean Cancer Association This article is protected by copyright. All rights reserved.
(n=12) including one patient with relapsed DLBCL who was initially diagnosed with angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS; n=8); other subtypes included ENKTL (n=7), PMBCL (n=3), transformed MF (n=2), and AITL (n=1). The median percentage of CD30-positive tumor cells was 50% (range, 30-100%), and 60% of patients (n=20) had  50% of CD30 expression (Table 1 ).
Efficacy
Twelve patients achieved CR (n=6) or PR (n=6) and four patients' best response was SD;
thus, the overall disease control rate was 48.5% (16/33) . However, the remaining 17 patients
were dropped due to early progressive disease after the first or second BV cycle. Among 12 patients with CR or PR, six (4CR, 2PR) completed 16 cycles, maintaining their response, whereas the others showed disease progression during treatment (Fig. 1A) . A 70-year-old female patient with PTCL-NOS discontinued the treatment because she developed a stroke prior to her second cycle. Although her response evaluation showed SD, she could not receive further treatment. The waterfall plot for responders showed a significant change from baseline tumor size compared to nonresponders (Fig. 1B) . The median number of treatment cycles was two (range, 1 to 16), however, the median cycle number for the 16 patients with CR, PR, or SD was 7.5. The overall rates of disease control in patients with DLBCL (2CR, 2PR, 2SD; 6/12, 50%), PTCL-NOS (2CR, 1PR, 2SD; 5/8, 62.5%), and transformed MF (2PR; 2/2, 100%) were higher compared with those with ENKTL (1CR, 1PR; 2/7, 29%), PMBCL (1CR; 1/3, 33%), and AITL (0/1, 0%) albeit with small subtype samples ( Fig. 2A) . When response to BV was compared based on disease status prior to BV, there was no significant difference between patients with relapsed (3CR, 2PR, 1SD; 6/11, 54.5%) and refractory disease (3CR, 4PR, 3SD; 10/22, 45.5%,
p=0.721). Korean Cancer Association
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CD30 expression in responding patients
Although we only enrolled patients with high-CD30-expressing NHL, this sample had a wide range of CD30 expression values (30%-100%). Based on their percentage of CD30-positive tumor cells, patients were grouped as 30%-49% (n=13), 50%-79% (n=9), or 80%-100%
(n=11). The number of patients with CR and PR did not differ significantly based on these groupings (46%, 6/13 vs. 11%, 1/9 vs. 46%, 5/11, p=0.182) (Fig. 2B) . Nor did overall disease control rate differ (46%, 6/13 vs. 22%, 2/9 vs. 64%, 7/11) (p=0.180). Although transformed MF (n=2; patients 25 and 26) showed 90% and 100% CD30 expression, respectively, their best response was PR and was not durable (Fig. 1) . No other subtypes showed a significant association between CD30 expression and response to BV.
Survival outcome
With a median follow-up of 29.2 months (95% CI, 28.7 to 29.7 months), eight patients were alive and their best responses were 4CR, 3PR, and 1PD. Among these, two patients (patients 13 and 16) maintained CR without any evidence of disease relapse. Five responders (2CR, 3PR) showed relapse or disease progression during treatment or after completion of 16 cycles; however, they were alive because of rescue by subsequent chemotherapies, including one case of transformed MF (patient 26) who receiving allogeneic SCT (Fig. 1) . The one patient with ENKTL showing early PD (patient 27) was alive after responding to salvage treatments.
Thus, the median duration of objective response (CR and PR) was 6.0 months (range, 3.9 to 35.0 months). However, the remaining patients died and the majority showed early PD after the first or second cycle of BV. As a result, the median PFS and OS for all patients were 1.9 months (95% CI, 0.6 to 3.2 months) and 6.1 months (95% CI, 4.5 to 7.7 months), respectively (Fig. 2C) .
OS among patients responding to BV was significantly better than that of patients with SD or Korean Cancer Association This article is protected by copyright. All rights reserved.
PD (Fig. 2D) . Although not statistically significant, the survival outcome among patients who were refractory to previous treatments prior to BV was inferior to that of patients with relapsed disease after a previous treatment (Fig. 2E) . However, OS did not differ based on CD30 expression (30%-49% vs. 50%-79% vs.  80%) (Fig. 2F) . Nor did OS differ between subtypes, although these samples were small (data not shown).
Adverse events
Treatment-emergent adverse events were reported in 31 patients (93.9%), all of which are summarized in Table 2 . Grade 3 or worse adverse events occurred in 23 patients (69.7%).
Serious adverse events were reported in 18 patients (54.5%); the most common serious adverse event was fever (n=4). Other serious adverse events included herpes zoster (n=2), urinary tract infection (n=1), sinusitis (n=1), dyspnea (n=1), diarrhea (n=1), anorexia (n=1), and perianal abscess (n=1). Increase in creatinine was associated with tumor lysis syndrome (n=1). Suicide attempt occurred in one patient (patient 11) after the first cycle; however, the patient was able to continue receiving BV until PD. Patient 19's serious adverse event, stroke, led to study discontinuation (Fig. 1) . The remaining three patients were admitted to the hospital due to disease progression during the study. The most common adverse events, occurring in  20% of patients, included fever (39%), neutropenia (30%), fatigue (24%), and peripheral sensory neuropathy (27%) (Table2). Gastrointestinal symptoms, including diarrhea, nausea, and vomiting were also commonly observed, and upper respiratory infection, rhinosinusitis, and skin rash were common adverse events in  10% of patients (Table 2 ).
Biomarker analysis for predicting outcome of BV treatment
EBV positivity was not significantly associated with the percentage of CD30 expression Korean Cancer Association This article is protected by copyright. All rights reserved.
in the analysis of 29 patients with available EBV status (Fig. 3A) . MUM1 expression was assessed by immunohistochemistry in 24 patients whose tumor tissue was available for study.
Nine patients showed negativity for MUM1 (DLBCL 1, PMBCL 1, PTCL 3, ENKTL 4) whereas the remaining 15 patients were positive for MUM1 (DLBCL 9, PMBCL 2, PTCL 2, ENKTL 2). MUM1 negativity was more common in 30%-49% of CD30 expression whereas MUM1-negative cases were not observed in 80%-100% of CD 30 expression (Fig. 3B) . Among nine patients negative for MUM1, five responded to BV (4CR, 1PR, 55.6%), whereas only two responded to BV (1CR, 1PR, 13.3%) out of the 15 MUM1-positive patients (Fig. 3C) . Although their association with response was not statistically significant (p=0.061), the PFS and OS of MUM1-negative patients were significantly higher compared with MUM1-positive patients ( Fig. 3D and E) . When response was compared based on EBV positivity of tumor cells, using 29 patients with available EBV status, the response to BV among patients with EBV-positive tumor (35.3%, 6/17) did not differ significantly from those with EBV-negative tumors (25.0%, 3/12; p=0.694). Accordingly, OS did not differ between EBV-positive and -negative patients (p=0.588) (Fig. 3F ).
Heterogeneity of response
Patients' best responses could be clearly identified by PET/CT because patients achieving CR showed complete disappearance of FDG uptake ( Fig. 4A and B) . However, some patients showed heterogeneous responses of involved sites. For example, one patient with PTCL (patient 18) showed PR after the second cycle (Fig. 4C) . His remaining target lesions disappeared after the twelfth cycle, although new lesions appeared. He continued to receive BV, based on the investigator's decision; however, PD was discovered 2 months after the completion of planned treatment. Two patients (patients 3 and 4) with DLBCL showed PD after Korean Cancer Association This article is protected by copyright. All rights reserved.
the second cycle of BV, although their responses differed according to the sites involved, with several lesions disappearing and others progressing ( Fig. 4D and E) .
Discussion
The study purpose was to determine the overall disease control rate from BV administration among heavily pretreated relapsed or refractory patients with various subtypes of NHL, other than ALCL and HL. Because our study sample was included based on CD30-positive tumor cells being  30%, regardless of histologic subtype, patients with various subtypes of NHL, from DLBCL to MF, could be enrolled. Considering the study population would be relapsed or refractory patients who were heavily pretreated with intensified cytotoxic chemotherapies, we thought the achievement of SD could be beneficial for those patients who did not have few options for alternative treatment. That was why we designated the overall disease control rate as a primary endpoint instead of objective response rate. Our hypothesis was that CD30 expression-based BV administration would improve the treatment outcome.
Although the overall response rate of 36% (12/33) was lower than expected, the overall disease control rate (48.5%, 16/33) satisfied the primary endpoint (40%). Furthermore, six patients maintained their response up to 12 months and could complete the planned number of treatment cycles (Fig. 1A) . When our results were compared with that of previous studies for patients with aggressive NHL, the median duration of responders (6.0 months) was comparable to that of previous studies (Table 3) . However, the median PFS for all patients (1.9 months) was shorter than that of previous studies with DLBCL (4.0 months), and PTCL (2.6 months), and the different nature of our study population including ENKTL might be associated with relatively poorer outcome than previous studies [6, 7] . Although only two patients with transformed MF Korean Cancer Association This article is protected by copyright. All rights reserved.
were enrolled in our study, they all showed PR. This favorable outcome of our study was consistent with the phase III study demonstrating superior efficacy of BV to physician's choice for CD30-positive cutaneous T-cell lymphoma [24] . However, the relatively low response rate of the CD30 expression-based BV administration in our study suggested that the extent of CD30 expression might not predict the response to BV. Thus, the outcome from BV may be independent of CD30 expression in consistent with previous studies.
There are several potential explanations for this unexpectedly poor outcome among patients with CD30 expression  30%. First, the immunohistochemistry for CD30 used tumor samples available to the study at patient enrollment. Thus, some patients' samples were from their diagnosis whereas others' were from their point of relapse or progression. Possible changes in CD30 expression from diagnosis to relapse might influence BV-based outcomes.
Second, CD30 could be expressed heterogeneously depending on site although we could not perform multiple biopsies in the same patient. If we could evaluate the extent of CD30 expression in different sites of the same patients, the patterns of CD30 expression might differ, possibly leading to different response patterns to BV. Indeed, disease progression was observed even when the target lesion disappeared (Fig. 4) . Third, the downregulation of CD30 expression could be related to disease progression during treatment. An in vitro study using the ALCL cell line Karpas-299 showed a reduction in the percentage of CD30-positive cells after long-term BV treatment [25] . Thus, continuous BV treatment may induce downregulation of CD30 expression in tumor cells, leading to drug resistance. In fact, we observed several cases showing disease progression during treatment even though they initially showed response to BV (Fig. 1 ).
Another mechanism of resistance to antibody-drug conjugate is the expression of drug exporter proteins such as multidrug-resistance protein 1 (MDR1) [25] . Because monomethyl auristatin E is a chemotherapeutic drug affected by MDR1, a drug efflux protein, this may have Korean Cancer Association This article is protected by copyright. All rights reserved.
contributed to the poor outcome from BV seen in this study. Inhibition of MDR1 has been reported to overcome resistance to BV and show synergism with BV in a mouse xenograft model [26] . A recent phase I study combining cyclosporine, an MDR1 inhibitor, with BV showed an overall response rate of 67% (CR 33%) in primary BV refractory HL patients. These results might support the role of MDR1 in the resistance to BV [27] . Considering that ENKTL tumor cells are well known to express MDR1, the unsatisfactory outcome of ENKTL could be explained by MDR1 expression of tumor cells although we did not evaluate the MDR1 expression of ENKTL patients participating in this study [28] .
In a post-hoc analysis to explore biomarkers predicting response to BV, EBV positivity was not significantly associated with the percentage of CD30 expression, whereas MUM1 negativity was more common in 30%-49% of CD30 expression, and MUM1-negative cases
were not observed in 80-100% of CD30 expression ( Fig. 3A and B) . This indicates that EBV positivity may be a cause of CD30 expression, although it may not be related to the extent of CD30 expression. However, as MUM1 expression could be activated by CD30 through NF-B activation, all cases with > 80% of CD30 expression showed MUM1 positivity while MUM1-negative cases were observed in cases with < 50% of CD30 expression (Fig. 3B) . Accordingly, EBV positivity was unrelated to response to BV, whereas MUM1 expression showed a tendency toward association with response to BV (Fig. 3C) . Furthermore, the OS and PFS of MUM1-negative patients were significantly better than those of MUM1-positive patients ( Fig.   3D and E). Given that this analysis was based on 24 patients with DLBCL, PMBCL, PTCL, and ENKTL, which usually follow aggressive courses after relapse, our findings suggest that MUM1 status may serve as a parameter for predicting both response to BV and survival outcome after BV treatment. Further, our study showed low frequency of MUM1 expression in ENKTL compared with PTCL, which is consistent with our previous study [29] . Thus, the poor Korean Cancer Association This article is protected by copyright. All rights reserved.
response to BV in ENKTL patients of our study might be more related to aforementioned MDR1 expression rather than MUM1 because MDR1 expression is common in ENKTL.
However, the association of MDR1 with the response to BV in various subtypes of NHL should be evaluated by additional studies because MDR1 can be expressed and cause resistance to chemotherapy in other subtypes, especially EBV-positive T-cell lymphoproliferative disorders [30] .
In this study, the most common adverse events, occurring in  20% of patients, included fever (39%), neutropenia (30%), fatigue (24%), and peripheral sensory neuropathy (27%), which is consistent with previous studies [31, 32] . Other side effects, such as gastrointestinal symptoms and upper respiratory infection, were manageable. Although several cases showed central nervous system toxicity and required management, including one suicide attempt after the first cycle, these were all manageable. Thus, the trial's safety profile was comparable with previous experiences with BV and the side effects that occurred were not problematic during treatment, despite our enrollment of heavily pretreated patients with relapsed or refractory lymphomas. This manageable safety profile of BV in relapsed or refractory lymphoma suggested it could be combined with other chemotherapeutic drugs having non-overlapping toxicity. Indeed, a recent phase III study for patients with CD30-positive PTCL showed a significantly improved survival with manageable safety profile in patients receiving the frontline treatment of BV plus CHP (cyclophosphamide, doxorubicin, and prednisone) compared to patients treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) [33] .
In conclusion, the single-agent activity of BV was acceptable in terms of disease control rate and toxicity profiles in patients with relapsed or refractory high-CD30-expressing NHL. 
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